|Research and Markets: Gram-Positive Bacterial Infections Global Clinical ...|
Our clinical trial report, Gram-Positive Bacterial Infections Global Clinical Trials Review, H2, 2014" provides data on the Gram-Positive Bacterial Infections clinical trial scenario. This report provides elemental information and data relating to the ...
Stockhouse - Thu, 18 Dec 2014 05:41
|FDA approvals boost 2 Mass. biotech firms|
The current flagship Cubist drug, Cubicin, generates more than $1 billion a year in revenue worldwide targeting infections from Gram-positive bacteria. Zerbaxa has the potential to become as big a seller, according to projections from Cubist and ...
Boston Globe - Fri, 19 Dec 2014 14:59
|FDA Approves Second Cubist Antibiotic Of 2014|
Forbes - Fri, 19 Dec 2014 15:26
|Cubist Pharmaceuticals: An Extraordinary Arbitrage Opportunity|
Seeking Alpha - Wed, 17 Dec 2014 08:30
|RI hospital find bacterial infections differ based on geography, healthcare ...|
... thrive in warm and moist environments, compared to another group of bacteria referred to as Gram-positive bacteria. The study also found that the proportion of a country's GDP spent on health care impacted the type of bacteria causing such infections.
EurekAlert (press release) - Thu, 18 Dec 2014 11:07
|XYDALBA™ (dalbavancin) Receives CHMP Positive Opinion for the Treatment ...|
XYDALBA is marketed in the United States as DALVANCE® (dalbavancin) for injection. DALVANCE® is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by Susceptible Gram-positive bacteria, ...
PR Newswire (press release) - Fri, 19 Dec 2014 13:11
|CHMP Backs Dalbavancin (Xydalba) for Acute Skin Infections|
Medscape - Fri, 19 Dec 2014 12:03
|Durata Therapeutics (DRTX) Receives Positive CHMP Opinion on Xydalba as ...|
StreetInsider.com (subscription) - Fri, 19 Dec 2014 04:56
|Experimental Drug Shows Dramatic Improvement Against Bacterial Infection in ...|
In this study, the research team sought to determine if a possible alternative to traditional antibiotics known as “eCAPs” (engineered cationic antimicrobial peptides), are indeed effective in treating both gram-positive and negative bacteria as well ...
Cystic Fibrosis News Today - Wed, 17 Dec 2014 11:30
|FDA Approves Pathogen Reduction System to Treat Platelets|
Examples of some of the pathogens that may be reduced using the Intercept Blood System include HIV, hepatitis B and C viruses, West Nile virus and Gram-negative and Gram-positive bacteria. The Intercept process also reduces the number of T cells (a ...
Infection Control Today - Fri, 19 Dec 2014 06:15
|Here Is Why Cerus Corporation (CERS) Stock Is Soaring|
Bidness ETC - Thu, 18 Dec 2014 02:52
|Health Care Sector Update for 12/17/2014: CERS,ASPX,POZN|
Nasdaq - Wed, 17 Dec 2014 10:33
|Cerus Corp (CERS) Confirms FDA Approval of INTERCEPT Blood System for ...|
StreetInsider.com (subscription) - Tue, 16 Dec 2014 14:30
|Bloodstream infections differ based on distance from the equator, health care ...|
... compared to another group of bacteria referred to as Gram-positive bacteria. The study also found that the proportion of a country's GDP spent on health care impacted the type of bacteria causing such infections. The study was published in the ...
News-Medical.net - Fri, 19 Dec 2014 01:00
|New treatment effectively inhibited bacterial growth|
Montelaro and colleagues tested the efficacy of engineered cationic antimicrobial peptides, or eCAPs, which were synthesized in the laboratory and have shown broad activity in vitro against both gram-negative and gram-positive pathogens, including ...
Healio - Mon, 15 Dec 2014 13:22